Covered recipient · General Payments record
SCOTT LAWRENCE FLEISCHAUER
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$18.82
2 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Education | $18.82 | 2 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $18.82 | 2 |
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SCOTT LAWRENCE FLEISCHAUER
NPI 1285789065 · CMS profile ID 57953
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
ARLINGTON, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1285789065?year=2020&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SCOTT LAWRENCE FLEISCHAUER, NPI 1285789065, CMS profile ID 57953. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1285789065?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). SCOTT LAWRENCE FLEISCHAUER, NPI 1285789065, CMS profile ID 57953. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1285789065?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- SCOTT LAWRENCE FLEISCHAUER, NPI 1285789065, CMS profile ID 57953, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1285789065?year=2020&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
2 matching records · $18.82 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–2 of 2.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| PFIZER INC. | $10.70 | 09/16/2020 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743806295 | CMS |
| PFIZER INC. | $8.12 | 08/21/2020 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743583081 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2023 | Principal investigator | $82,946.55 | 11 |
| PY2022 | Principal investigator | $30,457.88 | 33 |
| PY2021 | Principal investigator | $116,928.89 | 44 |
| PY2020 | Recipient | $656.00 | 1 |
| PY2020 | Principal investigator | $144,873.80 | 55 |
| PY2019 | Recipient | $3,698.00 | 1 |
| PY2019 | Principal investigator | $153,312.17 | 57 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
58 records in PY2019
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Amgen Inc. | $390.00 | 12/24/2019 | Non-covered Recipient Entity US ONC RESEARCH LLC | Prospective Observational Study of Onpro vs SOC | No dispute reported | 06/30/2026 | 675778647 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $8,500.00 | 12/23/2019 | Non-covered Recipient Entity Us Oncology Research Llc | Single arm study with Regorafenib and Nivolumab in MSS CRC | No dispute reported | 06/30/2026 | 629166407 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $190.00 | 11/15/2019 | Non-covered Recipient Entity Texas Oncology, P.A. | PCYC-1134M-CA | No dispute reported | 06/30/2026 | 673103725 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $190.00 | 11/15/2019 | Non-covered Recipient Entity Texas Oncology, P.A. | PCYC-1134M-CA | No dispute reported | 06/30/2026 | 673104347 |
| Principal investigator 1 | Incyte Corporation | $22.80 | 11/08/2019 | Non-covered Recipient Entity MCKESSON SPECIALTY PHARMACY LP | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY | No dispute reported | 06/30/2026 | 666518929 |
| Principal investigator 1 | Incyte Corporation | $0.48 | 11/08/2019 | Non-covered Recipient Entity MCKESSON SPECIALTY PHARMACY LP | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY | No dispute reported | 06/30/2026 | 666518931 |
| Principal investigator 1 | Incyte Corporation | $0.90 | 11/08/2019 | Non-covered Recipient Entity MCKESSON SPECIALTY PHARMACY LP | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY | No dispute reported | 06/30/2026 | 666518935 |
| Principal investigator 1 | Incyte Corporation | $176.00 | 11/08/2019 | Non-covered Recipient Entity MCKESSON SPECIALTY PHARMACY LP | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY | No dispute reported | 06/30/2026 | 666518937 |
| Principal investigator 1 | Incyte Corporation | $22.80 | 11/08/2019 | Non-covered Recipient Entity MCKESSON SPECIALTY PHARMACY LP | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY | No dispute reported | 06/30/2026 | 666518979 |
| Principal investigator 1 | Incyte Corporation | $65.88 | 11/08/2019 | Non-covered Recipient Entity MCKESSON SPECIALTY PHARMACY LP | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY | No dispute reported | 06/30/2026 | 666518985 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,060.00 | 11/05/2019 | Non-covered Recipient Entity Us Oncology Res Llc | A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC Nivolumab as Maintenance after Induction Chemotherapy or as First Line Treatment, Alone or in Combination of Standard of Care Therapies | No dispute reported | 06/30/2026 | 639761517 |
| Principal investigator 1 | Incyte Corporation | $850.00 | 10/15/2019 | Non-covered Recipient Entity TX ONC | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY | No dispute reported | 06/30/2026 | 666457797 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $638.00 | 10/15/2019 | Non-covered Recipient Entity Texas Oncology, P.A. | PCYC-1134M-CA | No dispute reported | 06/30/2026 | 673102465 |
| Principal investigator 1 | PFIZER INC. | $7,370.00 | 10/04/2019 | Non-covered Recipient Entity US Oncology Research LLC | PHASE 2 STUDY IN PATIENTS WITH NEOADJUVANT BREAST CANCER | No dispute reported | 06/30/2026 | 671660227 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $97.05 | 09/19/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY ARLINGTON SOUTH | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive TPS 50 | No dispute reported | 06/30/2026 | 691367293 |
| Principal investigator 1 | Incyte Corporation | $489.00 | 09/15/2019 | Non-covered Recipient Entity TX ONCOLOGY-BEAUMONT, MAMIE MCFADDIN WARD CANCER CENTER | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY | No dispute reported | 06/30/2026 | 666487609 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $190.00 | 09/15/2019 | Non-covered Recipient Entity Texas Oncology Southwest Fort Worth Pet | PCYC-1134M-CA | No dispute reported | 06/30/2026 | 673101944 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $190.00 | 09/15/2019 | Non-covered Recipient Entity Texas Oncology Southwest Fort Worth Pet | PCYC-1134M-CA | No dispute reported | 06/30/2026 | 673102085 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $60.00 | 08/15/2019 | Non-covered Recipient Entity Us Oncology Res Llc | A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC Nivolumab as Maintenance after Induction Chemotherapy or as First Line Treatment, Alone or in Combination of Standard of Care Therapies | No dispute reported | 06/30/2026 | 639761513 |
| Principal investigator 1 | Incyte Corporation | $850.00 | 07/15/2019 | Non-covered Recipient Entity TX ONCOLOGY-BEAUMONT, MAMIE MCFADDIN WARD CANCER CENTER | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY | No dispute reported | 06/30/2026 | 666487607 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $638.00 | 07/15/2019 | Non-covered Recipient Entity Texas Oncology Southwest Fort Worth Pet | PCYC-1134M-CA | No dispute reported | 06/30/2026 | 673102195 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,779.20 | 07/12/2019 | Non-covered Recipient Entity Us Oncology Res Llc | A Phase IIIbIV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen | No dispute reported | 06/30/2026 | 639761507 |
| Principal investigator 1 | Incyte Corporation | $32.00 | 06/10/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A.- MCALLEN | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY | No dispute reported | 06/30/2026 | 666511373 |
| Principal investigator 1 | Incyte Corporation | $22.08 | 06/10/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A.- MCALLEN | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY | No dispute reported | 06/30/2026 | 666511385 |
| Principal investigator 1 | Genentech, Inc. | $104.00 | 05/21/2019 | Non-covered Recipient Entity PHYSICIANS RELIANCE NETWORK US ONCOLOGY RESEARCH INC | GAZYVA GA101 PLUS BENDA CLL | No dispute reported | 06/30/2026 | 681079703 |
| Principal investigator 1 | Genentech, Inc. | $52.00 | 05/21/2019 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | GAZYVA GA101 PLUS BENDA CLL | No dispute reported | 06/30/2026 | 681085833 |
| Principal investigator 1 | Genentech, Inc. | $130.00 | 05/21/2019 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | GAZYVA GA101 PLUS BENDA CLL | No dispute reported | 06/30/2026 | 681090941 |
| Principal investigator 1 | Genentech, Inc. | $26.00 | 05/21/2019 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | GAZYVA GA101 PLUS BENDA CLL | No dispute reported | 06/30/2026 | 681091613 |
| Principal investigator 1 | Genentech, Inc. | $136.60 | 05/21/2019 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | GAZYVA GA101 PLUS BENDA CLL | No dispute reported | 06/30/2026 | 681093099 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $256.00 | 05/15/2019 | Non-covered Recipient Entity Texas Oncology Southwest Fort Worth Pet | PCYC-1134M-CA | No dispute reported | 06/30/2026 | 673098307 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,756.00 | 05/01/2019 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC Nivolumab as Maintenance after Induction Chemotherapy or as First Line Treatment, Alone or in Combination of Standard of Care Therapies | No dispute reported | 06/30/2026 | 639761515 |
| Principal investigator 1 | Incyte Corporation | $361.00 | 04/15/2019 | Non-covered Recipient Entity TX ONCOLOGY-BEAUMONT, MAMIE MCFADDIN WARD CANCER CENTER | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY | No dispute reported | 06/30/2026 | 666487589 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $956.00 | 04/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiationand as maintenance therapy versus chemoradiation alone in subjects with locally advancedhead and neck squamous cell carcinoma | No dispute reported | 06/30/2026 | 691305938 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $190.00 | 04/15/2019 | Non-covered Recipient Entity Texas Oncology Southwest Fort Worth Pet | PCYC-1134M-CA | No dispute reported | 06/30/2026 | 673097711 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $190.00 | 04/15/2019 | Non-covered Recipient Entity Texas Oncology Southwest Fort Worth Pet | PCYC-1134M-CA | No dispute reported | 06/30/2026 | 673098203 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $190.00 | 04/15/2019 | Non-covered Recipient Entity Texas Oncology Southwest Fort Worth Pet | PCYC-1134M-CA | No dispute reported | 06/30/2026 | 673098615 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $638.00 | 04/15/2019 | Non-covered Recipient Entity Texas Oncology Southwest Fort Worth Pet | PCYC-1134M-CA | No dispute reported | 06/30/2026 | 673098789 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,089.84 | 04/10/2019 | Non-covered Recipient Entity Us Oncology Res Llc | Studying Interventions for Managing Patients With Chronic Myeloid Leukemia CML in Chronic Phase The 5-Year Prospective Cohort Study SIMPLICITY | No dispute reported | 06/30/2026 | 639761505 |
| Principal investigator 1 | Incyte Corporation | $573.89 | 04/03/2019 | Non-covered Recipient Entity VIRGINIA CANCER SPECIALISTS-FAIRFAX | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY | No dispute reported | 06/30/2026 | 666459903 |
| Principal investigator 1 | Incyte Corporation | $5,279.08 | 04/03/2019 | Non-covered Recipient Entity VIRGINIA CANCER SPECIALISTS-FAIRFAX | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY | No dispute reported | 06/30/2026 | 666459909 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,014.60 | 03/12/2019 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | A Phase IIIbIV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen | No dispute reported | 06/30/2026 | 639761509 |
| Principal investigator 1 | Eli Lilly and Company | $27,967.00 | 03/12/2019 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 654298615 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $18.00 | 03/08/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiationand as maintenance therapy versus chemoradiation alone in subjects with locally advancedhead and neck squamous cell carcinoma | No dispute reported | 06/30/2026 | 691404063 |
| Principal investigator 1 | Amgen Inc. | $18,000.00 | 02/26/2019 | Non-covered Recipient Entity US ONC RESEARCH LLC | Prospective Observational Study of Onpro vs SOC | No dispute reported | 06/30/2026 | 675795993 |
| Principal investigator 1 | Amgen Inc. | $9,785.00 | 02/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | Prospective Observational Study of Onpro vs SOC | No dispute reported | 06/30/2026 | 675793904 |
| Principal investigator 1 | Celgene Corporation | $2,380.00 | 02/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY, P.A. | Celgene - Connect MM | No dispute reported | 06/30/2026 | 675419121 |
| Principal investigator 1 | Incyte Corporation | $489.00 | 02/15/2019 | Non-covered Recipient Entity TX ONC | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY | No dispute reported | 06/30/2026 | 666457789 |
| Recipient | Eli Lilly and Company | $3,698.00 | 01/22/2019 | Covered Recipient Physician | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 654283705 |
| Principal investigator 1 | Genentech, Inc. | $7,872.80 | 01/21/2019 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | GAZYVA GA101 PLUS BENDA CLL | No dispute reported | 06/30/2026 | 681093097 |
| Principal investigator 1 | Eli Lilly and Company | $0.13 | 01/17/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 654297385 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,150.00 | 01/15/2019 | Non-covered Recipient Entity Texas Oncology | Phase IIIb IV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 639761511 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,620.00 | 01/15/2019 | Non-covered Recipient Entity Texas Oncology | SUSTAIN, event driven trial | No dispute reported | 06/30/2026 | 639761519 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $9,334.00 | 01/15/2019 | Non-covered Recipient Entity Texas Oncology | Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in US Community Oncology Practices | No dispute reported | 06/30/2026 | 639761521 |
| Principal investigator 1 | Eli Lilly and Company | $24,251.04 | 01/15/2019 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 654297643 |
| Principal investigator 1 | Incyte Corporation | $850.00 | 01/15/2019 | Non-covered Recipient Entity TX ONCOLOGY-BEAUMONT, MAMIE MCFADDIN WARD CANCER CENTER | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY | No dispute reported | 06/30/2026 | 666487641 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $638.00 | 01/15/2019 | Non-covered Recipient Entity Texas Oncology, P.A. | PCYC-1134M-CA | No dispute reported | 06/30/2026 | 673093483 |
| Principal investigator 1 | Pharmacyclics LLC, An AbbVie Company | $190.00 | 01/15/2019 | Non-covered Recipient Entity Texas Oncology, P.A. | PCYC-1134M-CA | No dispute reported | 06/30/2026 | 673093543 |
| Principal investigator 1 | Eli Lilly and Company | $5,000.00 | 01/14/2019 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH NIVOLUMAB VS. NIVOLUMAB ALONE AS SECOND-LINE THERAPY IN SUBJECTS WITH STAGE IV / METASTATIC WILD TYPE NON-SMALL CELL LUNG CANCER AND LOW TUMOR EXPRESSION OF PD-L1 | No dispute reported | 06/30/2026 | 654297809 |